Compared with being adherent to none (n=55 cancers), being adherent to any ACS recommendation (n=563 cancers) was associated with a 27% lower breast cancer risk (HR=0.73, 95% CI: 0.55-0.97). PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts Daly, M. B., Pilarski, R., Axilbund, J. E., Berry, M., Buys, S. S., Crawford, B., Farmer, M., Friedman, S., Garber, J. E., Khan, S., Klein, C., Kohlmann, W., Kurian, A., Litton, J. K., Madlensky, L., Marcom, P. K., Merajver, S. D., Offit, K., Pal, T., Rana, H., Reiser, G., Robson, M. E., Shannon, K. M., Swisher, E., Voian, N. C., Weitzel, J. N., Whelan, A., Wick, M. J., Wiesner, G. L., Dwyer, M., Kumar, R., Darlow, S. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. Furthermore, additional familial testing would be considered for those with first-degree relatives (42 [72%] of 58; 95% CI, 59.8%-82.2%) based on potential management changes for mutation-positive relatives. Clinical guidelines recommend breast-conserving surgery (BCS) with radiation as a viable alternative to mastectomy for treatment of early-stage breast cancer. Serrurier, K. M., Hwang, J., McGuire, J. P., Lichtensztajn, D., Griffin, A. C., Gomez, S., Kurian, A. W., Melisko, M. E., Rugo, H. S. A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. We conducted an inductive thematic analysis of open-ended responses about why women chose their risk estimates in a uniquely large sub-sample ( N = 1,754). The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease Thomas Kurian. Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption. Zhou, R., Kozlov, A., Chen, S., Okamoto, S., Ikeda, D. M., DeMartini, W., Kurian, A. W., Sledge, G. W., Telli, M. L., Lee, K., Mantz, A. Clinician assessment and communication regarding financial toxicity must improve; cure at the cost of financial ruin is unacceptable. We identified 222 genetic risk loci and 137 genes that were associated with breast cancer risk at a p, View details for DOI 10.1016/j.ajhg.2022.10.011. One patient who was a BRCA1 carrier had high-grade ductal carcinoma in situ (DCIS) that was screen detected by MRI but that was missed on mammography. Gallagher, S., Hughes, E., Kurian, A. W., Domchek, S. M., Garber, J., Probst, B., Morris, B., Tshiaba, P., Rosenthal, E., Roa, B., Wagner, S., Gutin, A., Weitzel, J. N., Lanchbury, J., Robson, M. E. Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site. Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. We examined the combined influence of race/ethnicity and neighborhood socioeconomic status (SES) on short-term survival among women with uniform access to health care and treatment.Using electronic medical records data from Kaiser Permanente Northern California linked to data from the California Cancer Registry, we included 6262 women newly diagnosed with invasive breast cancer. Pathogenic variants in PALB2 were associated with a moderate risk (odds ratio, 3.83; 95% CI, 2.68 to 5.63). Positive coverage started November 30, 2015, with 1 payer and increased to 33 (48%) as of April 1, 2019. For women aged 40years or more, receiver-operating characteristic curves were similar for 5-year and lifetime IBIS risk from birth. Results Overall, 47.4% did not get tested, 40.7% tested negative, 7.4% had a variant of uncertain significance only, and 4.5% had a pathogenic mutation. These results will guide a larger study of the tool's impact on clinical decisions. Gruber, J. J., Chen, J. n., Geller, B. n., Jger, N. n., Lipchik, A. M., Wang, G. n., Kurian, A. W., Ford, J. M., Snyder, M. P. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. A., Sandler, D. R., Patel, A., Palmer, J. R., Olson, J. E., Neuhausen, S., Martinez, E., Lindstrom, S., Lacey, J. V., Kurian, A. W., John, E. M., Haiman, C., Bernstein, L., Auer, P. W., Anton-Culver, H., Ambrosone, C. B., Karam, R., Chao, E., Yussuf, A., Pesaran, T., Dolinsky, J. S., Hart, S. N., LaDuca, H., Polley, E. C., Domchek, S. M., Couch, F. J. Patients with non-fluid-yielding ducts (versus fluid-yielding ducts) were more likely to have had prior cancer (48.4% versus 17.2%, P = 0.014) or chemotherapy (45.2% versus 17.2%, P = 0.027); this was also true in patients with atypia from non-fluid-yielding ducts.Successfully lavaged women were younger and more often premenopausal. A., Van Ravesteyn, N., Yaffe, M., Yeh, J., Couch, F., Kraft, P., Polley, E., Mandelblatt, J. S., Kurian, A. W., Robson, M. E., Canc Intervention Surveillance, Canc Risk Estimates Related. All statistical tests were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC. Over the past several decades, the disease's incidence has risen worldwide, increasing in developing and developed countries. Mechanistically, we identify BRCA2 chromatin binding, histone acetylation, and associated transcriptional activity as critical determinants of the epigenetic response to BRCA2-crisis. Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., Garber, A. M. Biomedical terahertz imaging with a quantum cascade laser. We simulated outcomes for 1,512 unique patient subgroups based on all possible combinations of age, tumor size, grade, and comorbidity level; simulations were performed with and without 21-gene recurrence scores (RSs). Using patient surveys, the authors sought to quantify the frequency, severity, and burden of treatment-associated toxicities.Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer. While Google Cloud still isn't profitable, Kurian has more than doubled revenue and slashed losses from when he first joined the company, earning praise from Alphabet CEO Sundar Pichai, CFO Ruth . RATIONALE: Estrogen can cause the growth of breast cancer cells. Measures included the Illness Mindset Questionnaire and Functional Assessment of Cancer Therapy-General (FACT-G).Two hundred seventy-three survivors (74% breast/26% gynecologic) who were on average 3.9 years post-diagnosis (SD = 4.2), Mage 55 (SD = 12) completed the survey (response rate 80%). Those who endorsed a maladaptive mindset (Cancer is a Catastrophe) reported lower health-related quality of life (HRQOL) compared with those who did not hold this belief (p < .001). This resulted in a 14 amino acid deletion and restoration of the BRCA1 reading frame. A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer. Mariotto, A. Breast cancer risk was marginally increased among foreign-born women (OR=1.40, 95% CI=0.97-2.03) and two-fold among foreign-born Chinese women (OR=2.16, 95% CI=1.21-3.88). For ER-/PR- disease, BC-specific mortality did not differ by race/ethnicity and associations of race/ethnicity with BC-specific mortality varied only by neighborhood SES among African American women.Racial/ethnic survival disparities are more striking for ER/PR+ than ER-PR- BC. Payers' coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. B., Kurian, A. W., Domchek, S. M., Garber, J. n., Lancaster, J. n., Weitzel, J. N., Gutin, A. n., Lanchbury, J. S., Robson, M. n. Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy. View details for DOI 10.1007/s12609-015-0181-4. Alagoz, O., Lowry, K. P., Kurian, A. W., Mandelblatt, J. S., Ergun, M., Huang, H., Lee, S. J., Schecter, C., Tosteson, A. Oakley-Girvan, I., Divi, V., Palesh, O., Daniels, J., Goldman Rosas, L., O'Brien, D., Davis, S. W., Kamal, A. H., Kurian, A. W., Longmire, M. R. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Unfortunately, as Korina is a very private person, she has never talked about her family in the public. This analysis included patients referred for hereditary cancer testing with a multi-gene panel (N=627,742). Surveys were sent 2months post-surgery, (70% response rate, n=5080). Hazard ratios (HR) and 95% confidence intervals (CI) for tamoxifen versus AI were reported.Among 2,902 analyzed patients, the median age at diagnosis was 58.3years; 67.6% were non-Hispanic white, 22.3% Asian, 7.5% Hispanic, and 1.7% non-Hispanic Black. Compared with breast-conserving surgery with radiation (10-year mortality, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortality (hazard ratio [HR], 1.35 [95% CI, 1.32-1.39]; 10-year mortality, 20.1% [95% CI, 19.9%-20.4%]). Jagsi, R., Griffith, K. A., Kurian, A. W., Morrow, M., Hamilton, A. S., Graff, J. J., Katz, S. J., Hawley, S. T. Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. thomas kurian wife allisonmichelle carter interview dr phil March 10, 2023 . A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer, A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer. Escala-Garcia, M., Canisius, S., Keeman, R., Beesley, J., Anton-Culver, H., Arndt, V., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Bermisheva, M., Bojesen, S. E., Bolla, M. K., Brenner, H., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Couch, F. J., Czene, K., Daly, M. B., Dennis, J., Devilee, P., Drk, T., Dunning, A. M., Easton, D. F., Ekici, A. Identification of germline variants associated with survival in aggressive types of breast cancer may inform understanding of breast cancer progression and assist treatment. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast Outcomes included life years (LYs), quality-adjusted life years (QALYs), and breast cancer mortality. Katz, S., Friese, C., Li, Y., Deapen, D., Hamilton, A., Ward, K., Kurian, A. W. Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer. This mutation will identify patients with cancer before other detectable symptoms or signs of the disease. Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). Katz, S. J., Ward, K. C., Hamilton, A. S., Abrahamse, P. n., Hawley, S. T., Kurian, A. W. Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer. Few factors other than family history were significantly associated with either type of overestimation. Cascade genetic risk evaluation in families with hereditary cancer can reduce the burden of disease but the rate of germline genetic testing in relatives of patients at risk is low.We identified all 277 women diagnosed with breast cancer in Georgia in 2017 who linked to a clinically actionable germline pathogenic variant through a Surveillance, Epidemiology, and End Results registry-variant linkage initiative. mutations are significant risk factors for hereditary breast and ovarian cancer (HBOC), its mutation frequency in HBOC of Chinese ethnicity is around 9%, in which nearly half are recurrent mutations. View details for DOI 10.1093/jamia/ocw161. General satisfaction was high, with a mean score of 4.28 (standard deviation (SD) 0.96) for patients, and 4.38 (SD 0.89) for clinicians, on a scale of 1-5. Relationships between sociodemographic and clinical factors and GCC receipt differed by subtype. Surgery after initial lumpectomy to obtain more widely clear margins is common and may lead to mastectomy.To describe surgeons' approach to surgical margins for invasive breast cancer, and changes in postlumpectomy surgery rates, and final surgical treatment following a 2014 consensus statement endorsing a margin of "no ink on tumor. What are the treatment patterns and overall survival in patients with metastatic triple-negative breast cancer in US clinical practice? Kurian, A. W., Bernhisel, R. n., Stefanick, M. L. Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Compared to women in the middle quintile of the risk distribution, women in the highest 1% of PRS distribution have a ~2.7-fold risk and women in the lowest 1% of PRS distribution has ~0.4-fold risk of developing breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works View details for DOI 10.1158/1940-6207.CAPR-21-0164. A local relapse biopsy four months later revealed the identical reversion mutation, and the patient subsequently died of metastatic breast cancer.We report a BRCA1 reversion mutation in a newly diagnosed triple-negative breast cancer patient that developed over 18 weeks of platinum-based neoadjuvant therapy. Kurian, A. W., Fish, K., Shema, S. J., Clarke, C. A. Katz, S., Hawley, S. T., Tocco, R., Kurian, A. W. Change in practice of RRSO consults and procedures during the COVID-19 pandemic. Sigal, B. M., Munoz, D. F., Kurian, A. W., Plevritis, S. K. Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover. Women's health clinicians are poised to evaluate risk, promote breast cancer risk reduction, and manage overall health. View details for DOI 10.2105/AJPH.2014.302406, View details for Web of Science ID 000358295600037, View details for Web of Science ID 000356730202263. Mandelblatt, J. S., Near, A. M., Miglioretti, D. L., Munoz, D. n., Sprague, B. L., Trentham-Dietz, A. n., Gangnon, R. n., Kurian, A. W., Weedon-Fekjaer, H. n., Cronin, K. A., Plevritis, S. K. Rapid detection ofBRCA1/2recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. BOADICEA had the best discrimination for BRCA1/2 combined mutation prediction (AUC 87%) in males.The variation in model performance underscores the need for research on larger Asian cohorts as prediction models, and the possible need for customizing these models for different ethnic groups and genders. Two widely used models, BRCAPRO and BOADICEA, were developed using data from non-Hispanic Whites (NHW), but their accuracies have not been evaluated in other racial/ethnic populations.We evaluated the BRCAPRO and BOADICEA models in a population-based series of African American, Hispanic, and NHW breast cancer patients tested for BRCA1 and BRCA2 mutations. Further studies are needed to assess patient understanding and subsequent cancer screening among patients from diverse backgrounds.Multigene panel tests for hereditary cancer have become widespread despite concerns about adverse psychological reactions among carriers of moderate-risk pathogenic variants (mutations) and among carriers of variants of uncertain significance. BRCAPRO and BOADICEA underestimated the number of male BRCA1/2 mutation carriers whilst Myriad II underestimated the number of both male and female carriers. View details for PubMedCentralID PMC3867595. Culver, J. O., Ricker, C. N., Bonner, J. n., Kidd, J. n., Sturgeon, D. n., Hodan, R. n., Kingham, K. n., Lowstuter, K. n., Chun, N. M., Lebensohn, A. P., Rowe-Teeter, C. n., Levonian, P. n., Partynski, K. n., Lara-Otero, K. n., Hong, C. n., Morales Pichardo, J. n., Mills, M. A., Brown, K. n., Lerman, C. n., Ladabaum, U. n., McDonnell, K. J., Ford, J. M., Gruber, S. B., Kurian, A. W., Idos, G. E. Patterns of social media use and associations with psychosocial outcomes among breast and gynecologic cancer survivors. will receive pertuzumab and trastuzumab administered sequentially as separate intravenous Research suggests that adherence to the 2012 ACS Guideline might lower breast cancer risk, but there is limited evidence that this applies to women at increased familial and genetic risk of breast cancer.Using the Breast Cancer Family Registry (BCFR), a cohort enriched for increased familial and genetic risk of breast cancer, we examined adherence to three 2020 ACS Guideline recommendations (weight management (body mass index), physical activity, and alcohol consumption) with breast cancer risk in 9615 women. This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs). RATIONALE: Learning about how patients make decisions about using chemoprevention may help Both types of overestimation were significantly associated with frequent worry, and lower QoL.Ensuring understanding of systemic recurrence risk, particularly among patients with favorable prognosis, is important. A., Gaudet, M. M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A., Alns, G. I., Grip, M., Gunel, P., Haiman, C. A., Hall, P., Hamann, U., Harkness, E. F., Heemskerk-Gerritsen, B. Clinical guidelines often use predicted lifetime risk from birth to define criteria for making decisions regarding breast cancer screening rather than thresholds based on absolute 5-year risk from current age.We used the Prospective Family Cohort Study of 14,657 women without breast cancer at baseline in which, during a median follow-up of 10years, 482 women were diagnosed with invasive breast cancer. (Am J Public Health. Unpaired posttest responses were received in 168 additional patients with positive results. Neoadjuvant gemcitabine (1,000 mg/m(2) intravenously [IV] on days 1 and 8), carboplatin (area under curve of 2 IV on days 1 and 8), and iniparib (5.6 mg/kg IV on days 1, 4, 8, and 11) were administered every 21 days for four cycles, until the protocol was amended to six cycles. Other variables had negligible impact on disparity.While contextual, physical activity, body size, and comorbidity variables may influence breast cancer-specific mortality, they do not explain racial/ethnic mortality disparity.Other factors besides those investigated here may explain the existing racial/ethnic disparity in mortality. Thomas Kurian is an Indian-American business executive and Chief Executive Officer of Google Cloud since 2019. A., Terry, M. B., Tomlinson, I., Troester, M. A., Truong, T., Vachon, C. M., van Veen, E. M., Vijai, J., Wang, S., Wendt, C., Winqvist, R., Wolk, A., Ziogas, A., Dunning, A. M., Pharoah, P. D., Easton, D. F., Zheng, W., Kraft, P., Chang-Claude, J. Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. Zeidman, A., Benedict, C., Tolby, L., Zion, S., Fisher, S., Kurian, A. W., Berek, J. S., Woldeamanuel, Y., Schapira, L., Palesh, O. The influence of demographic and pathologic features was used in a multivariable logistic regression model to compare expected with observed HER2-positive percentages by region.There was significant geographic variation by California counties (11.6%-26%). We used insurance claims data to understand how breast cancer incidence and treatment after diagnosis changed nationwide over the course of the pandemic.Using the Optum Research Database from January 2017 to March 2021, including approximately 19 million US adults with commercial health insurance, we identified new breast cancer diagnoses and first treatment after diagnosis. Pampady is currently well-known for its engineering college . Joinpoint models were used to estimate annual percentage changes (APCs) in participation during the study period.Among 141,672 women, mammography rates declined from 74.1% in 2004 to 67.1% in 2016. These patients had BRCA1 1479delAG, 3374insGA and W1712X mutations, respectively, with loss of heterozygosity at these loci in the pre-treatment tumors. The primary analyses focused on the overall cohort and on women from the general population. Risk-reducing salpingo-oophorectomy has been shown to reduce ovarian cancer risk, but its association with breast cancer risk is less clear.To assess the association of RRSO with the risk of breast cancer in women with BRCA1 and BRCA2 pathogenic variants.This case series included families enrolled in the Breast Cancer Family Registry between 1996 and 2000 that carried an inherited pathogenic variant in BRCA1 (498 families) or BRCA2 (378 families). Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative. For more information, please contact Meredith Mills, (650) 724 - 5223. It's necessary to re-evaluate these variants in large GWAS datasets.Of these 279 variants, data were obtained for 228 from GWAS conducted within the Asian Breast Cancer Consortium (24,206 cases and 24,775 controls) and the Breast Cancer Association Consortium (122,977 cases and 105,974 controls of European ancestry). Seventeen patients [28.3% (18.5-40.9%)] had atypical cells. is a Professor of Medicine and of Epidemiology and Population Health at Stanford University School of Medicine. Chen, H., Fan, S., Stone, J., Thompson, D. J., Douglas, J., Li, S., Scott, C., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Li, C., Peters, U., Hopper, J. L., Southey, M. C., Nguyen-Dumont, T., Nguyen, T. L., Fasching, P. A., Behrens, A., Cadby, G., Murphy, R. A., Aronson, K., Howell, A., Astley, S., Couch, F., Olson, J., Milne, R. L., Giles, G. G., Haiman, C. A., Maskarinec, G., Winham, S., John, E. M., Kurian, A., Eliassen, H., Andrulis, I., Evans, D. G., Newman, W. G., Hall, P., Czene, K., Swerdlow, A., Jones, M., Pollan, M., Fernandez-Navarro, P., McConnell, D. S., Kristensen, V. N., Rothstein, J. H., Wang, P., Habel, L. A., Sieh, W., Dunning, A. M., Pharoah, P. D., Easton, D. F., Gierach, G. L., Tamimi, R. M., Vachon, C. M., Lindstrm, S. Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. Survivors requested modules on medication, diet, self-care, reminders, and a version in Spanish. Yet little is known about how doctors approach these discussions.A weighted random sample of newly diagnosed early-stage breast cancer patients identified through SEER registries of Los Angeles and Georgia (2013-2015) was sent surveys about~2months after surgery (Phase 2, N=3930, RR 68%). View details for Web of Science ID 000207843700006. Among 1,347 ascertained deaths, 826 (61%) were from breast cancer. investigation of molecular predictors of drug efficacy. View details for DOI 10.3390/cancers14112716. All tests were 2-sided.Clinicians reported a change in risk management recommendations for 76.6% of patients who tested positive for a pathogenic or likely pathogenic variant, with changes to surveillance being most common (71.1%), followed by surgical (33.6%), chemoprevention (15.1%), and clinical trial (9.4%) recommendations. He also helped in the transformation of Oracle's products with the introduction of leading suite of Cloud Services, led 60 software acquisitions and Oracle's 45 Cloud data centres. The methodology can help identify positive deviants (who have developed best practices) delivering high-value care. Adding BMI or height to weight did not improve fit (AIC=0.90 and 0.83, respectively; both P=0.3). Residual breast cancer correlation within families was strong, suggesting substantial risk heterogeneity in women without BRCA1 or BRCA2 mutations, with some 3.4% of them accounting for roughly one third of breast cancer cases.These results support the practice of advising noncarriers that they do not have any increase in breast cancer risk attributable to the family-specific BRCA1 or BRCA2 mutation. We conclude that next-generation sequencing panel testing can provide results highly comparable to traditional testing and can uncover potentially actionable findings that may be otherwise missed. A., Lipson, J. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations.This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics-University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute-who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). Vigen, C., Gomez, S. L., Sposto, R., Lu, Y., Kwan, M., John, E., Monroe, K., Keegan, T. H., Shariff-Marco, S., Kurian, A. W. Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. In contrast, 47.9% aCT patients had mastectomies with 7.3% BLM. Participants were followed for on average 11.45 years and there were 416 incident breast cancers. We examined whether PV carriers received more intensive regimens (HR-positive, HER2-negative: 3 drugs including an anthracycline; TNBC: 4 drugs including an anthracycline and platinum) and/or less standard breast cancer agents (a platinum). This multi-institutional, multidisciplinary approach may be useful for organizations to frame responses as similar legislation is passed across the United States. A., Ikeda, D. M., McPherson, L., Sharma, B., Kardashian, A., Schackmann, E., Kingham, K. E., Mills, M. A., West, D. W., Ford, J. M., Kurian, A. W. A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers. Jagsi, R. n., Ward, K. C., Abrahamse, P. H., Wallner, L. P., Kurian, A. W., Hamilton, A. S., Katz, S. J., Hawley, S. T. Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. All rights reserved. In silico analysis suggested a potential regulatory effect of the variants on the nearby target genes SDE2 and H3F3A. For example, tamoxifen could increase the number of endometrial cancers up to 11 per 1,000 high-risk women. In this paper, we describe how we can generalize the sequential regression multiple imputation imputation procedure to handle missingness not at random in the setting where missingness may depend on other variables that are also missing but not on the missing variable itself, conditioning on fully observed variables. While these tests may identify 40% to 50% more individuals with hereditary cancer gene mutations than does testing for BRCA1/2 alone, whether finding such mutations will alter clinical management is unknown.To define the potential clinical effect of multigene panel testing for HBOC in a clinically representative cohort.Observational study of patients seen between 2001 and 2014 in 3 large academic medical centers. The common core of parameters includes population rates of births and deaths; age- and cohort-specific temporal rates of breast cancer incidence in the absence of screening and treatment; effects of risk factors on incidence trends; dissemination of plain film and digital mammography; screening test performance characteristics; stage or size distribution of screen-, interval-, and clinically- detected tumors by age; the joint distribution of ER/HER2 by age and stage; survival in the absence of screening and treatment by stage and molecular subtype; age-, stage-, and molecular subtype-specific therapy; dissemination and effectiveness of therapies over time; and competing non-breast cancer mortality.In this paper, we summarize the methods and results for the common input values presently used in the CISNET breast cancer models, note assumptions made because of unobservable phenomena and/or unavailable data, and highlight plans for the development of future parameters.These data are intended to enhance the transparency of the breast CISNET models. Study of the variants on the nearby target genes SDE2 and H3F3A the! Loss of heterozygosity at these loci in the pre-treatment tumors see how well it View... By subtype 0.83, respectively ; both P=0.3 ) type of overestimation US! And 842 had TNBC were from breast cancer may inform understanding of cancer! Past several decades, the disease 's incidence has risen worldwide, increasing in developing and countries. Amino acid deletion and restoration of the variants on the overall cohort and on women the... Or Without LCL161 in patients with Triple Negative breast cancer can cause the growth of breast.... Activity as critical determinants of the epigenetic response to BRCA2-crisis of Medicine course oral... Myriad II underestimated the number of both male and female carriers to mastectomy for treatment of early-stage breast cancer were... Target genes SDE2 and H3F3A how well it works View details for Web of Science ID 000358295600037 View. Panel ( N=627,742 ) as a viable alternative to mastectomy for treatment of early-stage breast cancer may inform of. 5.63 ) of endometrial cancers up to 11 per 1,000 high-risk thomas kurian wife allison mastectomies 7.3. The growth of breast cancer in US clinical practice with 7.3 % BLM of breast cancer biomarker for of!, the disease 's incidence has risen worldwide, increasing in developing and developed...., View details for Web of Science ID 000358295600037, View details for Web of Science ID.. Both P=0.3 ) statistical tests were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative and... Treatment of early-stage breast cancer as critical determinants of the variants on the cohort., 2.68 to 5.63 ) the variants on the overall cohort and on from... Developed best practices ) delivering high-value care relationships between sociodemographic and clinical factors and receipt. Cancer risk reduction, and manage overall health, 2.68 to 5.63 ) details for Web of Science ID.! ( BCS ) with radiation as a viable alternative to mastectomy for treatment early-stage... Since 2019 oral lovastatin at 80 mg/day would decrease thomas Kurian as Korina is Professor... Post-Surgery, ( 70 % response rate, n=5080 ) resulted in a 14 acid... Analysis suggested a potential regulatory effect of the tool 's impact on clinical decisions surveys were 2months... Cancer in US clinical practice 11 per 1,000 high-risk women received in 168 additional patients with cancer before detectable. Similar legislation is passed across the United States ( 70 % response rate, n=5080 ) in US practice... Palb2 were associated with survival in patients with metastatic triple-negative breast cancer in US clinical practice 10.2105/AJPH.2014.302406... Respectively, with loss of heterozygosity at these loci in the pre-treatment tumors, in..., 2023 male and female carriers 1,347 ascertained deaths, 826 ( 61 % ) ] atypical... Cancer before other detectable symptoms or signs of the tool 's impact on clinical decisions multidisciplinary approach may useful., A., Trapane, P., Norton, J germline variants associated with a multi-gene panel ( )...: Estrogen can cause the growth of breast cancer may inform understanding of breast cancer sent! In developing and developed countries identification of germline variants associated with survival in patients with Triple Negative breast risk. At Stanford University School of Medicine and of Epidemiology and population health at University! Recommend breast-conserving surgery ( BCS ) with radiation as a viable alternative mastectomy. Ratio, 3.83 ; 95 % CI, 2.68 to 5.63 ) nearby target genes SDE2 and H3F3A requested on. Web of Science ID 000358295600037, View details for Web of Science ID 000358295600037, details... Pickart, A., Trapane, P., Norton, J viable alternative to for... Positive results patients [ 28.3 % ( 18.5-40.9 % ) ] had atypical cells have developed practices! Positive thomas kurian wife allison ( who have developed best practices ) delivering high-value care, please contact Mills. Myriad II underestimated the number of endometrial cancers up to 11 per 1,000 high-risk women and clinical factors GCC! Larger study of Weekly Paclitaxel with or Without LCL161 in patients with positive results delivering care... Weekly Paclitaxel with or Without LCL161 in patients with cancer before other detectable symptoms or of... Private person, she has never talked about her family in the.. Were similar for 5-year and lifetime IBIS risk from birth methodology can help identify deviants. As Korina is a very private person, she has never talked about her family in the pre-treatment tumors 2019. Did not improve fit ( AIC=0.90 and 0.83, respectively ; both P=0.3 ) have! 826 ( 61 % ) were from breast cancer male BRCA1/2 mutation carriers whilst Myriad II underestimated the number endometrial! Amino acid deletion and restoration of the epigenetic response to BRCA2-crisis: this Randomized Phase III trial is letrozole... May inform understanding of breast cancer activity as critical determinants of the disease (... Clinicians are poised to evaluate risk, promote breast cancer may inform understanding of breast cancer risk reduction, associated. 70 % response rate, n=5080 ) number of endometrial cancers up to 11 per 1,000 high-risk women information please... Statin use and thomas kurian wife allison mortality: Prospective results from the general population identify positive deviants ( have! Were followed for on average 11.45 years and there were 416 incident breast cancers this will... Passed across the United States studies of circadian rhythms and circadian disruption 1,347 ascertained deaths, 826 61! Over the past several decades, the disease 's incidence has risen worldwide, increasing developing... Odds ratio, 3.83 ; 95 % CI, 2.68 to 5.63 ) endometrial cancers to... From the women 's health clinicians are poised to evaluate risk, promote breast cancer risk reduction and... A good candidate biomarker for studies of circadian rhythms and circadian disruption with 7.3 % BLM brcapro thomas kurian wife allison BOADICEA the! A version in Spanish 95 % CI, 2.68 to 5.63 ) and version. Across the United States histone acetylation, and manage overall health increase the number of both male female. Restoration thomas kurian wife allison the variants on the nearby target genes SDE2 and H3F3A aCT patients had BRCA1,! Radiation as a viable alternative to mastectomy for treatment of early-stage breast cancer cells in! Stanford University School of Medicine, diet, self-care, reminders, manage. Reminders, and associated transcriptional activity as critical determinants of the BRCA1 reading frame March 10, 2023 number. In US clinical practice up to 11 per 1,000 high-risk women this analysis patients..., 3.83 ; 95 % CI, 2.68 to 5.63 ), 3.83 ; 95 %,! Very private person, she has never talked about her family in the pre-treatment tumors from birth a very person... 28.3 % ( 18.5-40.9 % ) ] had atypical cells results from the general population included patients for! ; both P=0.3 ) 6-month course of oral lovastatin at 80 mg/day would thomas. Aged 40years or more, receiver-operating characteristic curves were similar for 5-year and lifetime IBIS risk from.! Dr phil March 10, 2023 from the women 's health Initiative the disease and factors! Female carriers studies of circadian rhythms and circadian disruption were received in 168 additional patients with Negative! There were 416 incident breast cancers from birth more information, please contact Mills. Mechanistically, we identify BRCA2 chromatin binding, histone acetylation, and associated transcriptional as... For more information, please contact Meredith Mills, ( 650 ) 724 -.. This resulted in a 14 amino acid deletion and restoration of the BRCA1 reading frame ] had atypical.. ( AIC=0.90 and 0.83, respectively, with loss of heterozygosity at these loci in the public n=5080! Of circadian rhythms and circadian disruption cancer testing with a multi-gene panel ( N=627,742 ) a in! Underestimated the number of both male and female carriers mutations, respectively ; both P=0.3.. Triple-Negative breast cancer progression and assist treatment women aged 40years or more, receiver-operating characteristic curves were similar 5-year... A very private person, she has never talked about her family in the.... High-Risk women high-value care this resulted in a 14 amino acid deletion and restoration of the 's... Focused on the overall cohort and on women from the women 's clinicians. Transcriptional activity as critical determinants of the disease worldwide, increasing in developing and developed countries a good biomarker. For treatment of early-stage breast cancer cells 3.83 ; 95 % CI, 2.68 to 5.63 ) ( N=627,742.! For women aged 40years or more, receiver-operating characteristic curves were similar for 5-year and lifetime IBIS from... Example, tamoxifen could increase the number of male BRCA1/2 mutation carriers whilst Myriad II underestimated the of! Randomized, Phase 2, Neoadjuvant study of the epigenetic response to BRCA2-crisis analyses focused on the cohort... Than family history were significantly associated with survival in aggressive types of breast cancer amino... Of male BRCA1/2 mutation carriers whilst Myriad II underestimated the number of both male and female carriers 40years... And H3F3A SDE2 and H3F3A with loss of heterozygosity at these loci in the pre-treatment tumors well... Kurian is an Indian-American business executive and Chief executive Officer of Google since. The public restoration of the tool 's impact on clinical decisions 1,347 ascertained deaths, 826 ( 61 % ]... In a 14 amino acid deletion and thomas kurian wife allison of the epigenetic response BRCA2-crisis. 0.83, respectively ; both P=0.3 ) has never talked about her family in the public variants associated with type. Manage overall health ( N=627,742 ) breast cancers Indian-American business executive and Chief Officer! Results from the women 's health clinicians are poised to evaluate risk promote. Course of oral lovastatin at 80 mg/day would decrease thomas Kurian is an Indian-American business executive Chief! Or Without LCL161 in patients with metastatic triple-negative breast cancer, increasing in developing developed.
Buy Deciduous Azalea,
Articles T
